COMP <GO>
PPCB vs ELAB // GROSS PROFIT MARGIN
Propanc Biopharma Inc. (NASDAQ) VS. PMGC Holdings Inc. (NASDAQ) • 15-METRIC TALLY: PPCB 1
— ELAB 2
■ METRIC PARITY
LAST: $1.84 (-12.80%) • MKT CAP: $2.2M
gross-margins
—
LAST: $2.60 (-1.51%) • MKT CAP: $2.1M
gross-margins
31.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PPCB VS. ELAB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PPCB | ELAB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 31.40% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.59% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | ELAB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.2 | 28.0 | -1.80 | ELAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.2M | $2.1M | $42.6K | PPCB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PPCB REV | ELAB REV | PPCB GROSS % | ELAB GROSS % | PPCB FCF | ELAB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $590.1K | — | 31.4% | -$405.2K | -$6.4M |
| FY 2024 | $0 | $0 | — | — | -$935.1K | -$5.5M |
| FY 2023 | $0 | $1.7M | — | — | -$1.1M | -$4.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PPCB // BETA —
ELAB // BETA —